ATE251179T1 - Zielgerichtete, zytotoxische anthracyclin-analoge - Google Patents

Zielgerichtete, zytotoxische anthracyclin-analoge

Info

Publication number: ATE251179T1
Authority: AT; Austria
Prior art keywords: nitrogen; halo; carbon; och2; excess
Prior art date: 1995-11-27

Application number

AT96938216T

Other languages

English (en)

Inventor

Andrew V Tulane Univer Schally

Avenue Tulane

Attila A Tulane Universit Nagy

Ren-Zhi Tulane University Cai

Original Assignee

Univ Tulane

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-27

Filing date

1996-11-14

Publication date

2003-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE251179(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-11-14 Application filed by Univ Tulane filed Critical Univ Tulane

2003-10-15 Application granted granted Critical

2003-10-15 Publication of ATE251179T1 publication Critical patent/ATE251179T1/de

Links

229940045799 anthracyclines and related substance Drugs 0.000 title abstract 2
231100000433 cytotoxic Toxicity 0.000 title 1
230000001472 cytotoxic effect Effects 0.000 title 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
229910052799 carbon Inorganic materials 0.000 abstract 4
125000001475 halogen functional group Chemical group 0.000 abstract 3
229910052757 nitrogen Inorganic materials 0.000 abstract 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 abstract 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
239000011260 aqueous acid Substances 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene group Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
-1 monounsaturated nitrogen-containing heterocyclic compound Chemical class 0.000 abstract 1
230000003472 neutralizing effect Effects 0.000 abstract 1
150000007530 organic bases Chemical class 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
125000006413 ring segment Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

AT96938216T 1995-11-27 1996-11-14 Zielgerichtete, zytotoxische anthracyclin-analoge ATE251179T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/562,652 US5843903A (en)	1995-11-27	1995-11-27	Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en)	1995-11-27	1996-11-14	Targeted cytotoxic anthracycline analogs

Publications (1)

Publication Number	Publication Date
ATE251179T1 true ATE251179T1 (de)	2003-10-15

Family

ID=24247176

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03010988T ATE401305T1 (de)	1995-11-27	1996-11-14	Synthese heterozyklischen verbindungen welche fünf- oder sechsringe enthalten
AT96938216T ATE251179T1 (de)	1995-11-27	1996-11-14	Zielgerichtete, zytotoxische anthracyclin-analoge

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT03010988T ATE401305T1 (de)	1995-11-27	1996-11-14	Synthese heterozyklischen verbindungen welche fünf- oder sechsringe enthalten

Country Status (27)

Country	Link
US (2)	US5843903A (de)
EP (2)	EP0863917B1 (de)
JP (2)	JP3987575B2 (de)
KR (2)	KR100467899B1 (de)
CN (2)	CN1166597C (de)
AT (2)	ATE401305T1 (de)
AU (1)	AU709539B2 (de)
BR (1)	BR9611647B1 (de)
CA (2)	CA2238574C (de)
CZ (1)	CZ297297B6 (de)
DE (2)	DE69630233T2 (de)
DK (2)	DK1384710T3 (de)
EA (1)	EA001372B1 (de)
ES (2)	ES2205067T3 (de)
HK (1)	HK1052920B (de)
HU (1)	HU229870B1 (de)
IL (3)	IL134685A (de)
IS (2)	IS2178B (de)
MX (1)	MX9804119A (de)
NO (2)	NO324035B1 (de)
NZ (1)	NZ322054A (de)
PL (3)	PL191781B1 (de)
PT (2)	PT863917E (de)
SK (2)	SK284392B6 (de)
UA (1)	UA67722C2 (de)
WO (1)	WO1997019954A1 (de)
ZA (1)	ZA969709B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6576239B1 (en)	1996-09-10	2003-06-10	The Burnham Institute	Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en)	1998-08-25	2001-01-30	The Burnham Institute	NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en)	1998-07-03	1998-09-02	Cyclacel Ltd	Delivery system
ATE419273T1 (de)	1998-11-13	2009-01-15	Cyclacel Ltd	Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
FR2786397B1 (fr) *	1998-11-30	2003-01-10	Synt Em	Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) *	1998-11-30	2002-12-27	Synt Em	Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en)	1999-02-16	2003-03-04	The Burnam Institute	NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en)	1999-06-21	2002-04-30	Inkine Pharmaceutical Company, Inc.	Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
CA2388844A1 (en) *	1999-11-12	2001-05-25	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
ES2274823T3 (es)	1999-12-29	2007-06-01	Immunogen, Inc.	Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
AU4267700A (en) *	2000-01-13	2001-07-19	Academia Sinica	Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
WO2001081426A2 (en) *	2000-04-26	2001-11-01	Biosynthema Inc.	Rgd (arg-gly-asp) coupled to (neuro)peptides
US7452964B2 (en)	2001-09-07	2008-11-18	Board Of Regents, The University Of Texas System	Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en)	2000-09-08	2004-09-02	Wadih Arap	Human and mouse targeting peptides identified by phage display
US7420030B2 (en)	2000-09-08	2008-09-02	The Board Of Regents Of The University Of Texas System	Aminopeptidase A (APA) targeting peptides for the treatment of cancer
KR100420007B1 (ko) *	2001-04-25	2004-03-02	노영쇠	안트라사이클린 유도체 및 이를 포함하는 항암제
PL369336A1 (en) *	2001-09-21	2005-04-18	The Administrators Of The Tulane Educational Fund	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
AU2003224644A1 (en) *	2002-02-27	2003-09-09	The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan	Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
BR0308090A (pt)	2002-03-01	2006-04-11	Univ Tulane	conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
US7544767B2 (en)	2002-04-05	2009-06-09	Burnham Institute For Medical Research	HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
ES2615484T3 (es) *	2002-05-21	2017-06-07	Daiichi Sankyo Company, Limited	Composiciones medicinales que contienen grelina
CA2484761C (en)	2002-05-24	2010-11-09	Angiotech International Ag	Compositions and methods for coating medical implants
US8313760B2 (en)	2002-05-24	2012-11-20	Angiotech International Ag	Compositions and methods for coating medical implants
JP2006515186A (ja)	2002-09-26	2006-05-25	アンジオテックインターナショナルアクツィエンゲゼルシャフト	血管周囲ラップ
US20040225077A1 (en)	2002-12-30	2004-11-11	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) *	2003-01-24	2004-10-14	Immunomedics, Inc.	Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en)	2003-02-19	2005-02-24	Tamara Minko	Complex drug delivery composition and method for treating cancer
CA2523197C (en) *	2003-04-22	2016-05-24	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Peptide vectors
AU2007221964B2 (en) *	2003-04-22	2008-12-11	Ipsen Pharma S.A.S.	Peptide vectors
US7097993B2 (en)	2003-06-25	2006-08-29	Wisconsin Alumni Research Foundation	Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) *	2004-03-10	2005-09-22	Threshold Pharmaceuticals, Inc.	Hypoxia-activated anti-cancer agents
US20070060534A1 (en) *	2005-06-30	2007-03-15	Threshold Pharmaceuticals, Inc.	Anthracycline analogs
JP5340155B2 (ja) *	2006-09-06	2013-11-13	エテルナツェンタリスゲゼルシャフトミットベシュレンクテルハフツング	細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (de)	2006-09-07	2008-03-19	AEterna Zentaris GmbH	Konjugate von Disorazol und seinen Derivaten mit Zell-bindenden Molekülen, neue Disorazolderivate, Verfahren zu deren Herstellung und deren Verwendung
US20100087370A1 (en) *	2007-02-14	2010-04-08	The General Hospital Corporation	Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) *	2007-12-27	2009-12-27	Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет	Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
US8742076B2 (en) *	2008-02-01	2014-06-03	Genentech, Inc.	Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
AU2009235897B2 (en) *	2008-04-11	2012-04-12	Tianjin Hemay Oncology Pharmaceutical Co., Ltd	Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
KR101328315B1 (ko) *	2008-04-11	2013-11-11	티안진 헤메이 바이오-텍 컴퍼니 리미티드	고활성의 안트라사이클린 항생물질 유도체, 이의 제조방법 및 사용
WO2010009124A2 (en)	2008-07-15	2010-01-21	Genentech, Inc.	Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
CA2752608A1 (en)	2009-02-20	2010-08-26	Ipsen Pharma S.A.S.	Cytotoxic conjugates having neuropeptide y receptor binding compound
CN102050856B (zh) *	2009-11-03	2014-04-30	天津和美生物技术有限公司	具有高活性的表阿霉素的衍生物及其制备和应用
ES2533710T3 (es)	2010-12-02	2015-04-14	Nerviano Medical Sciences S.R.L.	Proceso para la preparación de derivados de morfolinil antraciclina
CN105198966B (zh) *	2014-06-26	2019-06-21	中国人民解放军军事医学科学院毒物药物研究所	GnRH类似物-细胞毒分子缀合物、其制备方法及用途
WO2016004048A2 (en) *	2014-06-30	2016-01-07	Blend Therapeutics, Inc.	Targeted conjugates and particles and formulations thereof
EP3045540A1 (de)	2015-01-19	2016-07-20	Æterna Zentaris GmbH	Enzymatisches Verfahren zur regioselektiven Herstellung von N-Fmoc-doxorubicin-14-o-dicarboxylsäurenmonoestern
HK1259311A1 (zh)	2015-10-28	2019-11-29	Tva (Abc), Llc	Sstr靶向綴合物及其顆粒和製劑
US10450340B2 (en)	2017-02-16	2019-10-22	Monopar Therapeutics Inc.	3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
AU2019469641B2 (en) *	2018-11-13	2025-04-03	Provincial Health Services Authority	Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
EP4499663A1 (de)	2022-03-25	2025-02-05	Provincial Health Services Authority	Radioaktiv markierte verbindungen zur in-vivo-bildgebung von gastrinfreisetzendem peptidrezeptor (grpr) und behandlung von grpr-bedingten erkrankungen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3725350A (en) *	1972-04-26	1973-04-03	Commercial Soluents Corp	Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) *	1980-06-09	1981-11-10	Sidney Farber Cancer Institute, Inc.	N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) *	1982-07-20	1984-08-07	Sri International	Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
FI102355B1 (fi) *	1988-02-11	1998-11-30	Bristol Myers Squibb Co	Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5217955A (en) *	1989-09-15	1993-06-08	Biomeasure, Inc.	Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5304687A (en) *	1989-12-19	1994-04-19	Farmitalia Carlo Erba S.R.L.	Morpholinyl derivatives of doxorubicin and process for their preparation
ES2094136T3 (es) *	1989-12-19	1997-01-16	Pharmacia Spa	Intermediarios quirales de 1,5-diyodo-2-metoxi o benciloxi.
DK0450461T3 (da) *	1990-04-06	1995-10-23	Univ Tulane	LHRH-analoger
ATE124054T1 (de) *	1990-04-06	1995-07-15	Univ Tulane	Somatostatinanaloge.
JP3169425B2 (ja) *	1992-03-27	2001-05-28	三共株式会社	アジドペンタンサイクリトール
US6214345B1 (en) *	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates

1995
- 1995-11-27 US US08/562,652 patent/US5843903A/en not_active Expired - Lifetime
1996
- 1996-11-14 PT PT96938216T patent/PT863917E/pt unknown
- 1996-11-14 PL PL358737A patent/PL191781B1/pl unknown
- 1996-11-14 DE DE69630233T patent/DE69630233T2/de not_active Expired - Lifetime
- 1996-11-14 PL PL96326865A patent/PL187230B1/pl unknown
- 1996-11-14 ES ES96938216T patent/ES2205067T3/es not_active Expired - Lifetime
- 1996-11-14 CN CNB021439192A patent/CN1166597C/zh not_active Expired - Lifetime
- 1996-11-14 DK DK03010988T patent/DK1384710T3/da active
- 1996-11-14 EP EP96938216A patent/EP0863917B1/de not_active Expired - Lifetime
- 1996-11-14 SK SK628-98A patent/SK284392B6/sk unknown
- 1996-11-14 UA UA98063318A patent/UA67722C2/uk unknown
- 1996-11-14 PT PT03010988T patent/PT1384710E/pt unknown
- 1996-11-14 ES ES03010988T patent/ES2310222T3/es not_active Expired - Lifetime
- 1996-11-14 BR BRPI9611647-1A patent/BR9611647B1/pt not_active IP Right Cessation
- 1996-11-14 WO PCT/EP1996/005029 patent/WO1997019954A1/en not_active Ceased
- 1996-11-14 KR KR10-2004-7004548A patent/KR100467899B1/ko not_active Expired - Lifetime
- 1996-11-14 DE DE69637604T patent/DE69637604D1/de not_active Expired - Lifetime
- 1996-11-14 AU AU75722/96A patent/AU709539B2/en not_active Expired
- 1996-11-14 SK SK341-2004A patent/SK284672B6/sk not_active IP Right Cessation
- 1996-11-14 CN CNB961986050A patent/CN1137136C/zh not_active Expired - Lifetime
- 1996-11-14 JP JP52012397A patent/JP3987575B2/ja not_active Expired - Lifetime
- 1996-11-14 CZ CZ0135798A patent/CZ297297B6/cs not_active IP Right Cessation
- 1996-11-14 AT AT03010988T patent/ATE401305T1/de active
- 1996-11-14 EA EA199800492A patent/EA001372B1/ru not_active IP Right Cessation
- 1996-11-14 KR KR10-1998-0703948A patent/KR100445754B1/ko not_active Expired - Lifetime
- 1996-11-14 EP EP03010988A patent/EP1384710B1/de not_active Expired - Lifetime
- 1996-11-14 AT AT96938216T patent/ATE251179T1/de active
- 1996-11-14 DK DK96938216T patent/DK0863917T3/da active
- 1996-11-14 HU HU9903771A patent/HU229870B1/hu unknown
- 1996-11-14 CA CA002238574A patent/CA2238574C/en not_active Expired - Lifetime
- 1996-11-14 NZ NZ322054A patent/NZ322054A/en not_active IP Right Cessation
- 1996-11-14 CA CA002471775A patent/CA2471775C/en not_active Expired - Lifetime
- 1996-11-14 PL PL96358646A patent/PL188786B1/pl unknown
- 1996-11-20 ZA ZA9609709A patent/ZA969709B/xx unknown
- 1996-11-26 IL IL13468596A patent/IL134685A/en not_active IP Right Cessation
- 1996-11-26 IL IL11969196A patent/IL119691A/en not_active IP Right Cessation
1998
- 1998-05-05 IS IS4734A patent/IS2178B/is unknown
- 1998-05-15 NO NO19982252A patent/NO324035B1/no not_active IP Right Cessation
- 1998-05-25 MX MX9804119A patent/MX9804119A/es unknown
- 1998-07-15 US US09/116,125 patent/US6184374B1/en not_active Expired - Lifetime
2000
- 2000-02-23 IL IL13468500A patent/IL134685A0/xx unknown
2003
- 2003-07-09 HK HK03104934.8A patent/HK1052920B/zh not_active IP Right Cessation
2005
- 2005-03-01 NO NO20051111A patent/NO20051111L/no not_active Application Discontinuation
2006
- 2006-11-09 IS IS8567A patent/IS2634B/is unknown
- 2006-11-15 JP JP2006309698A patent/JP4778405B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU7572296A (en)	1997-06-19
PT1384710E (pt)	2008-10-08
CA2238574C (en)	2004-10-19
DK1384710T3 (da)	2008-11-17
WO1997019954A1 (en)	1997-06-05
DE69630233T2 (de)	2004-08-05
KR19990071672A (ko)	1999-09-27
IS2178B (is)	2006-12-15
UA67722C2 (en)	2004-07-15
SK62898A3 (en)	1999-06-11
HUP9903771A3 (en)	2000-07-28
PL326865A1 (en)	1998-10-26
EP0863917B1 (de)	2003-10-01
BR9611647B1 (pt)	2010-03-09
HUP9903771A2 (hu)	2000-02-28
CZ135798A3 (cs)	1998-10-14
NZ322054A (en)	1999-04-29
CN1202903A (zh)	1998-12-23
KR20040037176A (ko)	2004-05-04
HK1052920A1 (en)	2003-10-03
EP0863917A1 (de)	1998-09-16
IL119691A (en)	2002-02-10
IS2634B (is)	2010-06-15
CN1405127A (zh)	2003-03-26
CZ297297B6 (cs)	2006-11-15
EP1384710B1 (de)	2008-07-16
IL134685A (en)	2002-12-01
AU709539B2 (en)	1999-09-02
NO982252D0 (no)	1998-05-15
ZA969709B (en)	1997-08-25
IL134685A0 (en)	2001-04-30
PL188786B1 (pl)	2005-04-29
NO324035B1 (no)	2007-07-30
EA001372B1 (ru)	2001-02-26
KR100445754B1 (ko)	2004-12-08
US6184374B1 (en)	2001-02-06
PL191781B1 (pl)	2006-07-31
HK1052920B (zh)	2005-03-04
ES2205067T3 (es)	2004-05-01
EP1384710A1 (de)	2004-01-28
JP4778405B2 (ja)	2011-09-21
KR100467899B1 (ko)	2005-01-24
MX9804119A (es)	1998-09-30
PT863917E (pt)	2004-02-27
CN1166597C (zh)	2004-09-15
IS4734A (is)	1998-05-05
SK284392B6 (sk)	2005-03-04
IL119691A0 (en)	1997-02-18
BR9611647A (pt)	1999-02-23
JP2000502055A (ja)	2000-02-22
EA199800492A1 (ru)	1998-12-24
CA2238574A1 (en)	1997-06-05
US5843903A (en)	1998-12-01
DK0863917T3 (da)	2004-01-19
NO982252L (no)	1998-05-15
JP3987575B2 (ja)	2007-10-10
NO20051111L (no)	2005-03-01
HK1017363A1 (en)	1999-11-19
ES2310222T3 (es)	2009-01-01
HU229870B1 (en)	2014-10-28
DE69637604D1 (de)	2008-08-28
CN1137136C (zh)	2004-02-04
PL187230B1 (pl)	2004-06-30
CA2471775A1 (en)	1997-06-05
JP2007045845A (ja)	2007-02-22
SK284672B6 (sk)	2005-08-04
DE69630233D1 (de)	2003-11-06
IS8567A (is)	2006-11-09
ATE401305T1 (de)	2008-08-15
CA2471775C (en)	2008-01-29

Legal Events

Date

Code

Title

Description

2004-04-15

UEP

Publication of translation of european patent specification

Ref document number: 0863917

Country of ref document: EP

Publication	Publication Date	Title
DK0863917T3 (da)	2004-01-19	Målrettede cytotoksiske anthracyclin-analoger
SE9301911D0 (sv)	1993-06-03	New peptide derivatives
BR9813835A (pt)	2000-10-10	Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
BR9917080A (pt)	2002-03-12	Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
GEP20012388B (en)	2001-03-25	Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
NZ510489A (en)	2002-11-26	Pyrrolo-benzodiazine derivatives optionally linked to a solid support useful for treating gene based diseases or bacterial, parasitic and viral infections
MX9708452A (es)	1998-06-30	Inhibidores de sialidasa bacteriana y metodos para fabricar y usar la misma.
NZ302072A (en)	1999-01-28	1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
AR003137A1 (es)	1998-07-08	Una composicion farmaceutica para tratar la leucemia
DK0941975T3 (da)	2002-04-22	Injiceringscement indeholdende korrosionshæmmere
GR3032698T3 (en)	2000-06-30	Organic compounds
MX9303587A (es)	1994-01-31	Producto para el cuidado de lentes de contacto, para lentes de contacto duros o blandos.
TW339325B (en)	1998-09-01	Novel azepane derivatives, process for the preparation thereof and pharmaceutical composition containing the same
EA199800289A1 (ru)	1998-08-27	Производные пептидов
ATE228359T1 (de)	2002-12-15	Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ES2085078T3 (es)	1996-05-16	Uso de imino-derivados de etianaldehido para la fabricacion de un medicamento para el tratamiento de la hipertension.
AR015458A1 (es)	2001-05-02	Compuestos de tetrahidrofurano, y composicion farmaceutica que lo contiene.
EP1210948A4 (de)	2004-07-28	Arzneimittel zur behandlung von nervenerkrankungen
HUP9902556A2 (hu)	1999-12-28	Szinergetikus herbicid készítmény és eljárás annak alkalmazására
ATE221897T1 (de)	2002-08-15	Inhibitoren der blutplättchen-aggregation, die c- terminale aminosäurereste mit aminergen seitenketten enthalten
YU58300A (sh)	2002-09-19	Postupak za dobijanje 3-aminoalkohola